MUFG Americas Holdings Corp lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,239 shares of the medical research company’s stock after selling 307 shares during the quarter. MUFG Americas Holdings Corp’s holdings in Thermo Fisher Scientific were worth $2,328,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Thermo Fisher Scientific by 2.0% in the first quarter. BlackRock Inc. now owns 24,582,453 shares of the medical research company’s stock worth $5,075,294,000 after acquiring an additional 475,267 shares during the period. Wells Fargo & Company MN increased its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Wells Fargo & Company MN now owns 3,198,908 shares of the medical research company’s stock worth $660,446,000 after acquiring an additional 9,820 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Thermo Fisher Scientific by 3.2% in the second quarter. Dimensional Fund Advisors LP now owns 2,670,961 shares of the medical research company’s stock worth $553,246,000 after acquiring an additional 82,255 shares during the period. Brown Advisory Inc. increased its stake in shares of Thermo Fisher Scientific by 2.4% in the first quarter. Brown Advisory Inc. now owns 2,144,864 shares of the medical research company’s stock worth $442,830,000 after acquiring an additional 49,320 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Thermo Fisher Scientific by 1.7% in the second quarter. Janus Henderson Group PLC now owns 2,036,659 shares of the medical research company’s stock worth $421,880,000 after acquiring an additional 34,401 shares during the period. Hedge funds and other institutional investors own 85.93% of the company’s stock.

Shares of NYSE TMO opened at $239.19 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $177.29 and a 1 year high of $240.88. The firm has a market cap of $95.85 billion, a P/E ratio of 25.20, a PEG ratio of 1.73 and a beta of 1.13. The company has a current ratio of 1.58, a quick ratio of 1.11 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 25th. The medical research company reported $2.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.63 by $0.12. Thermo Fisher Scientific had a net margin of 10.36% and a return on equity of 16.28%. The firm had revenue of $6.08 billion for the quarter, compared to the consensus estimate of $5.90 billion. During the same period in the prior year, the firm posted $2.30 earnings per share. The firm’s quarterly revenue was up 21.8% compared to the same quarter last year. research analysts anticipate that Thermo Fisher Scientific Inc. will post 10.98 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 15th. Shareholders of record on Monday, September 17th will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.28%. The ex-dividend date is Friday, September 14th. Thermo Fisher Scientific’s payout ratio is 7.17%.

A number of brokerages recently issued reports on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $259.00 price target on the stock in a report on Monday, July 30th. Leerink Swann increased their price target on shares of Thermo Fisher Scientific from $239.00 to $255.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $233.00 to $242.00 and gave the stock an “overweight” rating in a report on Thursday, July 26th. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, July 24th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and set a $300.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 26th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $239.08.

In other Thermo Fisher Scientific news, insider Patrick M. Durbin sold 20,550 shares of the stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $233.87, for a total transaction of $4,806,028.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction on Monday, June 4th. The shares were sold at an average price of $212.00, for a total transaction of $530,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 168,050 shares of company stock worth $37,585,029. Insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: NASDAQ

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.